About
Conexeu Sciences Inc.
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair.
The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration.
Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis.
Conexeu Sciences Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Live Market Snapshot
Real-time price and trading activity
USD · NASDAQ:NASDAQ:CNXU
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-05-29 | $11.53 | $11.88 | $10.87 | $11.73 | $11.73 | +0.20 | 29,000 |
| 2026-05-28 | $13.90 | $13.90 | $11.18 | $11.58 | $11.58 | -2.32 | 46,700 |
| 2026-05-27 | $14.22 | $14.22 | $12.50 | $13.63 | $13.63 | -0.59 | 42,400 |
| 2026-05-26 | $14.70 | $15.64 | $13.00 | $13.77 | $13.77 | -0.93 | 45,400 |
| 2026-05-22 | $13.21 | $14.68 | $12.72 | $14.40 | $14.40 | +1.19 | 31,800 |
| 2026-05-21 | $13.50 | $17.50 | $12.31 | $13.07 | $13.07 | -0.43 | 87,900 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| D | May 21, 2026 | Notice of Exempt Offering of Securities |
| D | May 21, 2026 | Notice of Exempt Offering of Securities |
| 424B3 | May 15, 2026 | Prospectus |
| 8-K | May 15, 2026 | Current Report |
| 424B3 | May 15, 2026 | Prospectus |
| EFFECT | May 11, 2026 | Notice of Effectiveness |
| 424B4 | May 11, 2026 | Prospectus |
| CERT | May 11, 2026 | Certification by an exchange approving securities for listing |
| 8-A12B | May 11, 2026 | Registration of securities |
| S-1/A | Apr 17, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
David R. Bogart
Founder and Director
Sonia Thomas M.B.A.
Head of Strategy and Transformation
